Skip to Content

Flurbiprofen (Ophthalmic)


(flure BI proe fen)

Index Terms

  • Flurbiprofen Sodium

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Ophthalmic, as sodium:

Ocufen: 0.03% (2.5 mL) [contains edetate disodium, thimerosal]

Generic: 0.03% (2.5 mL)

Brand Names: U.S.

  • Ocufen

Pharmacologic Category

  • Nonsteroidal Anti-inflammatory Drug (NSAID), Ophthalmic


Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties

Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity, inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.

Use: Labeled Indications

Inhibition of intraoperative miosis


Hypersensitivity to flurbiprofen or any component of the formulation

Dosing: Adult

Ophthalmic anti-inflammatory/surgical aid: Ophthalmic: Instill 1 drop every 30 minutes, beginning 2 hours prior to surgery for a total of 4 drops in each affected eye.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment

No dosage adjustment provided in manufacturer's labeling.

Dosing: Hepatic Impairment

No dosage adjustment provided in manufacturer's labeling.


For ophthalmic use only; avoid contact of bottle tip with skin or eye.


Store at 15°C to 25°C (59°F to 79°F).

Drug Interactions

Corticosteroids (Ophthalmic): NSAID (Ophthalmic) may enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed. Exceptions: Loteprednol. Monitor therapy

Adverse Reactions

Frequency not defined.

Cardiovascular: Hyperemia (ocular)

Hematologic & oncologic: Hemorrhagic diathesis (ocular tissue; in conjunction with ocular surgery)

Ophthalmic: Anterior chamber eye hemorrhage, burning sensation of eyes (transient), eye irritation, miosis, mydriasis, stinging of eyes (transient)

Miscellaneous: Fibrosis (ocular)


Concerns related to adverse effects:

• Aspirin/NSAID sensitivity: Use with caution in patients with previous sensitivity to aspirin or other NSAIDs, including patients who experience bronchospasm, asthma, rhinitis, or urticaria following NSAID or aspirin.

• Bleeding/hemostasis: May increase bleeding time associated with ocular surgery. Use with caution in patients with known bleeding tendencies or those receiving anticoagulants.

• Delayed healing: Healing time may be slowed or delayed.

Special populations:

• Post-surgical patients: To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.

Pregnancy Risk Factor


Pregnancy Considerations

Adverse events were observed following systemic administration of flurbiprofen in animal reproduction studies; therefore, flurbiprofen ophthalmic is classified as pregnancy category C. Information related to systemic absorption following topical application of the eye drops has not been located. Systemic absorption would be required in order for flurbiprofen to cross the placenta and reach the fetus. Refer to the Flurbiprofen (Systemic) monograph for additional information.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience burning or stinging. Have patient report immediately to prescriber vision changes, eye pain, severe eye irritation, or bleeding in the eye (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.